Modified Self-Replicating mRNA for Rapid Vaccine Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Traditional inactivated vaccines and recombinant protein vaccines have complex production processes, making them unsuitable for rapid response to large-scale epidemics, while existing mRNA vaccines face challenges in immune response and production efficiency.

Innovation Solution

Development of modified self-replicating mRNA vaccines incorporating non-structural replicase domains from an α virus and functional nucleotide analogs such as pseudouridine, N1-methylpseudouridine, and 5-hydroxymethoxycytidine to enhance immunogenicity and evade immune surveillance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional inactivated vaccines and recombinant protein vaccines are used, then production safety is improved, but production cycle is extended and process complexity increases

Engineering Contradiction:

Improveproduction safetyVSAvoidproduction cycle

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent replaces traditional mechanical/biological vaccine production methods (cell culture, inactivation processes) with an mRNA-based in vitro transcription system. This substitution enables rapid vaccine production without complex biological manufacturing processes, directly resolving the contradiction between production safety and production cycle time.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Ease of manufacture

If conventional mRNA vaccines are used, then production simplicity is improved, but immune response strength is insufficient

Engineering Contradiction:

Improveproduction simplicityVSAvoidimmune response

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent creates a composite mRNA structure by integrating self-replicating elements (NSP sequences from alphavirus) with conventional mRNA vaccine components. This composite design maintains the simplicity of in vitro transcription while dramatically enhancing immune response through autonomous replication, resolving the contradiction between production simplicity and immune response strength.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The self-replicating mRNA vaccine uses endogenous cellular machinery to autonomously replicate the vaccine mRNA within host cells. This self-service mechanism amplifies the immune response without requiring increased external dosage or complex production processes, maintaining production simplicity while enhancing immune response.

Inventive Principle:

Principle #25Self-service

3Reliability

If self-replicating mRNA vaccine is used, then immune response is enhanced, but nucleotide modification requirements increase

Engineering Contradiction:

Improveimmune responseVSAvoidnucleotide modification

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent modifies nucleotide parameters by incorporating pseudouridine and other modified nucleotides into the self-replicating mRNA structure. This parameter change reduces immune recognition of the mRNA as foreign material while maintaining replication capability, thereby enhancing overall immune response to the antigen without excessive modification complexity.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250230196A1Modified self-replicating mRNA

Publication Date: 2025.07.17 IMMORNA (HANGZHOU) BIOTECHNOLOGY CO LTD

AI summary

The present invention belongs to the field of nucleotides and mRNA, and specifically relates to modified self-replicating mRNA. A polynucleotide fragment thereof comprises an integrated target fragment and one or more non-structural replicase domains from an α virus, the integrated target fragment comprising a functional nucleotide analogue; and the functional nucleotide analogue comprises: at least one among pseudouridine, N1-methylpseudouridine, 5-hydroxymethoxycytidine, and N6-methyladenosine.